Orchid Pharma Limited — Q3 FY26 earnings call

Call held 12 Feb 2026

Management summary

Orchid Pharma reported a challenging Q3 FY26 with sales declining 5% YoY to INR 207 crores and EBITDA margin compressing to 6% due to continued pricing pressure in the global antibiotics market and lower contribution from regulated markets. Despite these headwinds, the company saw sequential volume improvement, launched Exblifep in new geographies (Spain, Italy, UAE, Kuwait), and progressed its 7ACA project towards mechanical completion by September 2026. R&D investments increased to 1.5% of sales, and cost structures were reviewed to mitigate impacts.

Highlights

  • Sequential volume improvement compared to the previous quarter.

  • Exblifep sales commenced in Spain and Italy, growing over 200% on a small base.

  • Exblifep launched in UAE and Kuwait, marking commercial presence beyond Europe and India.

  • AMS platform EBITDA drag reduced significantly.

  • 7ACA project progressing, with mechanical completion targeted by September 2026.

  • R&D investments increased to approximately 1.5% of sales, targeting differentiated products.

  • Non-employee costs reduced by approximately 10% on a 9-month basis.

  • Seeing some green shoots of recovery in January in the antibiotics market, with Cefixime prices improving.

  • Teflaro generic launched in India in November, expected to be a good contributor to AMS revenues.

  • Cash in hand of INR 75 crores (INR 60 crores from QIP, INR 15 crores in FD) with unused working capital limits.

Concerns

  • Sales declined 5% YoY in Q3 FY26 to INR 207 crores (vs INR 217 crores last year).

  • 9-month sales declined 16% YoY to INR 574 crores (vs INR 684 crores last year).

  • EBITDA for Q3 was 6% (vs 17% last year) and 9-month EBITDA was 10% (vs 17% last year).

  • Gross margin for Q3 was around 31%, impacted by lower regulated market contribution.

  • Oral segment experienced approximately 12% price erosion and 10% quantity erosion on a 9-month basis.

  • Regulated markets contribution declined to approximately one-fourth of sales (historically one-third).

  • Continued stress and pricing pressure in the global antibiotics market.

  • Russian business, a large market for Cefixime, has taken a significant hit due to war/sanctions.

  • Competition from Chinese suppliers dumping products due to their domestic demand slowdown.

Key financials

3 periods

Headline

  • R&D Spend (% of Sales)
    1.5%

Q3 FY26

  • Sales
    ₹207 Cr
    YoY -4.6%
  • EBITDA Margin
    6%
  • Gross Margin
    31%

9-month FY26

  • Sales
    ₹574 Cr
    YoY -16.1%
  • EBITDA Margin
    10%
  • EBITDA
    ₹58 Cr
    YoY -49.6%

What they filed

Q1 FY27: revenue up 15.6%, net profit up 156.6% against the same quarter last year.

₹ Cr · quarterly
Line itemQ2 FY25Q3 FY25Q4 FY25Q1 FY26Q2 FY26Q3 FY26Q4 FY26Q1 FY27
Revenue223 217 237 263 194 −13%207 −5%368 +55%304 +16%
EBITDA30 26 28 -6 -1 −105%2 −94%30 +8%14 +348%
Net profit27 21 22 -6 -6 −121%-13 −161%26 +16%3 +157%
How to read this

₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.

Segment breakdown

  • Domestic vs Export (9-month basis)
    20% Domestic Share80% Export Share
  • Regulated vs Non-regulated (within exports)
    25% Regulated Share (Q3 FY26)75% Non-regulated Share (Q3 FY26)
  • Sterile vs Non-sterile API (9-month basis)
    33.3% Sterile Share66.7% Non-sterile Share

Capital allocation

high confidence
  • Debt Debt disclosed
    • New borrowing Drawn down for 7ACA project, out of a planned INR 450 crores. ₹170 Cr
    With respect to your question on the debt, we have planned a INR450 crores debt on the 7ACA project and the drawdown till now is INR170 crores.
  • M&A Teflaro (US Market) Acquisition · Signed

    To develop and launch Teflaro in the US market.

    Whereas for Teflaro, we have signed a term sheet with a partner, and we would be taking up the validation batches of API and FDFs.
  • M&A Exblifep (Key Geography) Licensing · Signed

    Commercialization of Exblifep in a key geography.

    A binding term sheet has been signed in one of the key geographies.
  • M&A Exblifep (Major Regulated Market) Licensing · Announced

    Commercialization of Exblifep in a major regulated market.

    In addition, we have executed a nonbinding term sheet in a major regulated market.
  • M&A Exblifep (UAE and Kuwait) Licensing · Closed

    Commercial launch of Exblifep in GCC region.

    In the GCC region, we have completed launches in United Arab Emirates and Kuwait. This marks the beginning of commercial presence of this molecule beyond Europe and India.
  • M&A Ceftazidime/Avibactam (Global) Licensing · Announced

    Commercialization of Ceftazidime/Avibactam product across various geographies.

    And on the commercial deals also, we are close to signing commercial deals for this product across world, many geographies.
  • Liquidity Cash ₹75 Cr Includes INR 60 crores from QIP funds and INR 15 crores in FD. Working capital limits are unused.
    Around INR75 crores of cash we have in hand, around INR60 crores from QIP funds and INR15 crores in FD. And the working capital limits are unused.

Guidance & targets

Capacity

  • 7ACA Project Mechanical Completion Capacity · 2026 · High confidence September
    We continue to target mechanical completion by September.

    — Manish Dhanuka

Production

  • 7ACA Project First Commercial Production Production · Q4 FY27 or Q1 FY28 · Medium confidence 1-2 quarters after mechanical completion
    So September is mechanical completion and then first commercial should take a quarter or 2 from that, water trials in 1 quarter and commercial production in the next.

    — Mridul Dhanuka

  • Cefiderocol India Finished Formulation Production Start Production · 2026 · High confidence December
    We would be able to start the production sometime in December.

    — Manish Dhanuka

Regulatory

  • Cefiderocol India Registration Regulatory · H1 FY28 · Medium confidence 5-6 months after production starts
    There will be maybe 5, 6 months of registration. And we are hopeful we will get a concurrent waiver since it is important for this molecule.

    — Manish Dhanuka

  • Teflaro US Filing Regulatory · 2026-2027 · Medium confidence This year or early next year
    So the filing should happen this year for both the products or maybe early next year.

    — Mridul Dhanuka

  • Ceftazidime/Avibactam US Filing Regulatory · 2026-2027 · Medium confidence This year or early next year

    — Mridul Dhanuka

Market Entry

  • Exblifep ROW Announcements Market Entry · Ongoing · Medium confidence 1-2 announcements every quarter
    We are very hopeful maybe every quarter, at least one or two announcements should happen.

    — Manish Dhanuka

  • Exblifep US Deal Signing Market Entry · 2026 · High confidence Within this year
    Hopefully, we should be signing U.S. deal within this year. That's the target. Last quarter, I reiterated. We'll take about 12 months.

    — Mridul Dhanuka

Sales

  • Hospital Segment Sales (Orchid's own marketing) Sales · FY27 · Low confidence INR 20 crores
    No, it doesn't grow that fast. I mean I'll be happy if we do INR20 crores.

    — Manish Dhanuka

Profitability

  • Regulated Market Margins Profitability · Ongoing · High confidence 40-65%
    With respect to regulated markets, our margins remain between 50 -- between 40% to 65%, I would say.

    — Manish Dhanuka

  • Non-regulated Market Margins Profitability · Ongoing · Medium confidence Improve
    So definitely, margins in nonregulated would improve.

    — Manish Dhanuka

Cost Competitiveness

  • 7ACA Plant Lowest Cost Producer Cost Competitiveness · By next year · High confidence Lowest cost producer of cephalosporin
    Okay. So that means that kind of makes us the lowest cost producer of cephalosporin by next year?

    — Mridul Dhanuka

What to watch in Q4 FY26

Exblifep US Deal Signing

Within this year (2026)
Current In advanced discussions with several companies
Target Deal signed

Why it matters

The US is the biggest market for Exblifep, and securing a deal is crucial for future royalty income and market penetration.

Hopefully, we should be signing U.S. deal within this year. That's the target.

Risks & concerns

  • Global Antibiotics Market Stress

    high

    Continued pricing pressure and a prolonged down cycle in the global antibiotics market, impacting sales and profitability.

    Management acknowledged

  • Regulated Market Contribution Decline

    medium

    Lower contribution from higher-margin regulated markets (down to ~one-fourth of sales) impacting overall gross margins.

    Management acknowledged

  • Russian Business Impact

    medium

    The Russian market, a significant contributor for Cefixime, has been severely impacted by geopolitical events and sanctions.

    Management acknowledged

  • Chinese Competition

    medium

    Increased competition from Chinese suppliers dumping products internationally due to their domestic demand slowdown.

    Management acknowledged

  • Inventory Devaluation

    low

    Some impact on gross margins due to inventory devaluation, but expected to be largely completed this quarter.

    Management acknowledged

Q&A highlights

6 direct
Oral segment price/quantity erosion and Sterile segment variation Direct
So 10% quantity erosion, 12% price erosion. This is on a 9-month basis. Sterile, I think on a 9-month basis, the quantity variation is about 10% and value basis is flat.

Clarifies the extent of pricing pressure and volume decline in core segments, providing a detailed breakdown for both oral and sterile products.

Asked by Viraj Parekh

Update on Teflaro and Avycaz filings for US market Partial
Yes, we are in the discussion of, you can say, advanced stages of signing of a partner agreement for both. I'm sure before our next quarter call, we may be able to announce some of the agreements. So the filing should happen this year for both the products or maybe early next year. ... Whereas for Teflaro, we have signed a term sheet with a partner, and we would be taking up the validation batches of API and FDFs.

Provides an updated timeline and status for key differentiated product filings, which are crucial for future growth and market entry.

Asked by Viraj Parekh

Potential opportunity size and timeline for Teflaro and Avycaz Partial
So Teflaro continues to be about $125 million to $150 million product. And the good thing is for Ceftazidime, Avibactam, the U.S. market has significantly increased from about almost $200 million, it has become more than $300 million, $350 million. So that's a good thing. We are still within the launch window.

Quantifies the significant market potential for these products in the US and confirms launch readiness despite acknowledging missed 180-day exclusivity.

Asked by Viraj Parekh

Debt and cash on hand, and 7ACA project funding Direct
With respect to your question on the debt, we have planned a INR450 crores debt on the 7ACA project and the drawdown till now is INR170 crores. ... Around INR75 crores of cash we have in hand, around INR60 crores from QIP funds and INR15 crores in FD. And the working capital limits are unused.

Provides clarity on current liquidity and the funding status of the critical 7ACA project, indicating financial stability.

Asked by Viraj Parekh

Gross margin expectations given current market environment Direct
So the gross margin this quarter was around 31%, and that is largely contributing for the lower EBITDA and profitability. ... With respect to regulated markets, our margins remain between 50 -- between 40% to 65%, I would say. ... So this quarter, particularly, the sales of the regulated business is much lesser. That has yielded in a lower margin.

Explains the reason for the current quarter's lower gross margin and provides an outlook for improvement as regulated market sales recover.

Asked by Viraj Parekh

Cefiderocol India launch timeline and waiver status Direct
Yes. So the project is on stream. The project work is going on fine. The API is already manufactured. We would be able to start the production sometime in December. ... There will be maybe 5, 6 months of registration. And we are hopeful we will get a concurrent waiver since it is important for this molecule.

Details the progress and expected launch timeline for Cefiderocol in India, a critical new product, and expresses confidence in regulatory waiver.

Asked by Rahul

Exblifep expansion beyond US/EU and commercialization agreements Direct
Yes, yes. We are talking all across the world for licensing. There are discussions going on in more than 10 countries right now. ... We are very hopeful maybe every quarter, at least one or two announcements should happen.

Highlights the global expansion strategy for new products and the potential for future revenue streams from multiple geographies.

Asked by Rahul

Impact of Penicillin G minimum import price (MIP) on Orchid Pharma Direct
So minimum imports see, our majority business is exports. Minimum import price does not apply for the exported goods. You can still import freely Penicillin G if you're exporting the goods manufactured out of that. So I don't see much impact for us largely.

Clarifies that a new government policy will not negatively impact Orchid Pharma due to its export-focused business model and existing advanced authorization processes.

Asked by Loveleen Bagga

3 min read 7 chapters

Detailed narrative

Q3 FY26 Financial Performance Overview

Orchid Pharma reported a challenging Q3 FY26 with sales of INR 207 crores, a 5% decline year-on-year from INR 217 crores. The 9-month sales also saw a significant drop of 16% to INR 574 crores compared to INR 684 crores in the previous year. EBITDA for the quarter stood at 6%, a sharp decrease from 17% last year, reflecting continued stress in the global antibiotics market and lower contribution from higher-margin regulated markets.

Antibiotics Market Dynamics and Margin Pressure

The core antibiotics market continued to face pricing pressure, with the oral segment experiencing approximately 12% price erosion and 10% quantity erosion on a 9-month basis. The gross margin for Q3 FY26 was around 31%, primarily due to a reduced share of regulated markets, which historically contribute 40-65% margins, now accounting for only about one-fourth of sales. Management noted some green shoots of recovery in January, with Cefixime prices showing improvement.

Differentiated Products and Pipeline Progress

Progress on differentiated products is gaining momentum. Exblifep sales have commenced in Spain and Italy, showing over 200% growth on a small base, and has been launched in UAE and Kuwait. The company is in advanced discussions for licensing Exblifep in 3-4 large markets and aims to sign a US deal within the year. For Teflaro and Ceftazidime/Avibactam, partner agreements are in advanced stages, with filings expected this year or early next, targeting US markets of $125-150 million and $300-350 million respectively.

7ACA Project and Backward Integration

The 7ACA project is progressing as per the revised execution plan, with all fermenters erected and mechanical completion targeted by September 2026. Commercial production is expected 1-2 quarters thereafter. This project is strategically critical for enhancing backward integration and achieving long-term cost competitiveness, with the objective of becoming the lowest-cost producer of cephalosporins by next year.

Cost Optimization and R&D Investments

In response to the challenging environment, Orchid Pharma critically reviewed its cost structure, resulting in a 10% reduction in non-employee costs on a 9-month basis. Despite cost optimization, R&D investments increased to approximately 1.5% of sales, up from less than 1% last year. These investments are focused on differentiated products and FDF development for regulated markets, aiming for long-term competitiveness and future benefits from the operational FDF plant in Chennai.

Cefiderocol Development and Market Entry

The Cefiderocol project is on track, with API production already underway and on stability. The company expects to start production of the finished formulation in December 2026, followed by 5-6 months for registration. Management is confident of receiving a clinical trial waiver for India, citing the urgent need to address AMR, and believes it would be an injustice to patients if access is delayed.

Capital Structure and Liquidity

For the 7ACA project, INR 170 crores of the planned INR 450 crores debt has been drawn down. The company maintains a healthy liquidity position with INR 75 crores cash in hand, comprising INR 60 crores from QIP funds and INR 15 crores in fixed deposits, with unused working capital limits. This provides financial flexibility for ongoing projects and operations.

This is an AI-generated summary of a publicly available earnings call transcript.
View original transcript

More Healthcare earnings calls